Vancouver, British Columbia – (February 27th, 2018)–BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) announces the award of a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to partner with Donald Miller, Ph.D., Professor, Department of Pharmacology and Therapeutics at the University of Manitoba, to fabricate new nanomaterial and focus on evaluation of these new nanomaterial for knocking down SSAT1 expression in various cells .The up regulation of SSAT enzyme has been clinically demonstrated by BioMark and others to be highly elevated in lung, breast, prostate and brain cancers.
President and CEO, Rashid Ahmed explains, “We are delighted to be working with Dr. Miller and his team at the University of Manitoba to help BioMark assess the potential of designing new nanomaterials that can be used to target the metabolic pathway associated in the up-regulation of SSAT for various cancers. Dr. Miller has domain expertise and over 20 years of experience in fabricating, evaluating and developing polymer and metal oxide based nanoparticle compounds and delivery systems for various applications including the brain. He will direct the project and supervise the design of these novel nanomaterial candidates which provide more options to deliver a knock down SSAT compound enabling a potential better treatment associated with various cancers.”
Rashid says, “BioMark is grateful to the Canadian government for awarding it yet another grant that supports work to advance this important technology toward commercialization.”